Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from HBM Holdings Ltd. ( (HK:2142) ) is now available.
HBM Holdings Ltd. has entered a strategic collaboration with Otsuka Pharmaceutical Co., Ltd. to advance the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager for autoimmune diseases. This agreement grants Otsuka an exclusive license for global rights, excluding Greater China, and includes potential payments to HBM Holdings of up to $670 million, as well as tiered royalties on future sales. This partnership is expected to enhance HBM’s positioning in the T-cell engager market and may lead to further collaborations.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on the development of bispecific antibodies using its proprietary fully human HBICE bispecific technology and Harbour Mice platform. The company is involved in creating treatments for autoimmune and oncological diseases.
Average Trading Volume: 11,463,801
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.51B
Find detailed analytics on 2142 stock on TipRanks’ Stock Analysis page.